心肌淀粉样变性的影像学诊断与研究进展

俞子恒; 严卉; 朱建华

doi:10.13201/j.issn.1001-1439.2018.04.022

心肌淀粉样变性的影像学诊断与研究进展

- 浙江大学附属第一医院心内科(杭州, 310003)

详细信息

通讯作者: 严卉,E-mail:michelleyan@zju.edu.cn

中图分类号: R542.2

收稿日期: 2017-09-29

Imaging diagnosis and research progress of cardiac amyloidosis

- Department of Cardiology, the First Affiliated Hospital of Zhejiang University, Hangzhou, 310003, China

More Information

Corresponding author: YAN Hui, E-mail: michelleyan@zju.edu.cn

Received Date: 29 September 2017

摘要

摘要: 心肌淀粉样变病情特殊, 易误诊, 预后极差, 早期缺乏有效的非创伤性诊断方法。本文拟对该疾病的各种较新的影像学诊断方式加以综述。
- 心肌淀粉样变 /
- 斑点追踪显像技术 /
- 诊断
Abstract: Cardiac amyloidosis, a special disease, is easy misdiagnosed and delayed due to the lack of early effective non-invasive diagnostic methods.Therefore, the purpose of this article is to review the new image diagnostic ways.
- cardiac amyloidosis /
- speckle-tracking imaging technology /
- diagnosis

HTML全文

参考文献(37)

[1]	Dubrey SW, Hawkins PN, Falk RH.Amyloid diseases the heart:assessment, diagnosis, and referral[J].Heart, 2011, 97 (1):75-84.
[2]	Banypersad SM, Moon JC, Whelan C, et al.Updates in cardiac amyloidosis:a review[J].J Am Heart Assoc, 2012, 1 (2):e000364.
[3]	Liu PP, Smyth D.Wild-type transthyretin amyloid cardiomyopathy:a missed cause of heart failure with preserved ejection fraction with evolving treatment implications[J].Circulation, 2016, 133 (3):245-247.
[4]	Merlini G, Comenzo RL, Seldin DC, et al.Immunoglobulin light chain amyloidosis[J].Expert Rev Hematol, 2014, 7 (1):143-156.
[5]	Merlini G, Wechalekar AD, Palladini G.Systemic light chain amyloidosis:an update for treating physicians[J].Blood, 2013, 121 (26):5124-5130.
[6]	Eli Muchtar, Lori A, Blauwet MA, et al.Restrictive cardiomyopathy genetics, pathogenesis, clinical manifestations, diagnosis, and therapy[J].Circ Res, 2017, 121 (7):819-837.
[7]	Goldstein DS.Cardiac dysautonomia and survival in hereditary Transthyretin amyloidosis.JACC Cardiovasc Imaging, 2016, 9 (12):1442-1445.
[8]	Dispenzieri A, Buadi F, Kumar SK, et al.Treatment of immunoglobulin light chain amyloidosis:Mayo Stratification of Myeloma and Risk-Adapted Therapy (mS-MART) Consensus Statement[J].Mayo Clin Proc, 2015, 90 (8):1054-1081.
[9]	Davis MK, Kale P, Liedtke M, et al.Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era[J].Am J Transplant, 2015, 15 (3):650-658.
[10]	Hu K, Liu D, Nordbeck P, et al.Impact of monitoring longitudinal systolic strain changes during serial echocardiography on outcome in patients with AL amyloidosis[J].Int J Cardiovasc Imaging, 2015, 31 (7):1401-1412.
[11]	PRichards DB, Cookson LM, Berges AC, et al.Therapeutic clearance of amyloid by antibodies to serum amyloid P component[J].N Engl J Med, 2015, 373 (12):1106-1114.
[12]	Sher T, Fenton B, Akhtar A, et al.First report of safety and efficacy of daratumumab in 2cases of advanced immunoglobulin light chain amyloidosis[J].Blood, 2016, 128 (15):1987-1989.
[13]	Grogan M, Gertz M, McCurdy A, et al.Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis:The Mayo Clinic experience[J].World J Transplant, 2016, 6 (2):380-388.
[14]	Sajgalik P, Grupper A, Edwards BS, et al.Current status of left ventricular assist device therapy[J].Mayo Clin Proc, 2016, 91 (7):927-940.
[15]	Castaño A, Drachman BM, Judge D, et al.Natural history and therapy of TTR-cardiac amyloidosis:emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs[J].Heart Fail Rev, 2015, 20 (2):163-178.
[16]	Algalarrondo V, Antonini T, The'audin M, et al.Cardiac dysautonomia predicts long-term survival in hereditary transthyretin amyloidosis after liver transplantation[J].JACC Cardiovasc Imaging, 2016, 9 (12):1432-1441.
[17]	Azevedo Coutinho MDC, Cortez-Dias N, Cantinho G, et al.Progression of myocardial sympathetic denervation assessed by 123I-MIBG imaging in familial amyloid polyneuropathy and the effect of liver transplantation[J].Rev Port Cardiol, 2017, 36 (5):333-340.
[18]	Quarta CC, Solomon SD, Uraizee I, et al.Left ventricular structure and function in transthyretinrelated versus light-chain cardiac amyloidosis[J].Circulation, 2014, 129 (18):1840-1849.
[19]	Rapezzi C, Quarta CC, Obici L, et al.Disease profile and differential diagnosis of hereditary transthyretinrelated amyloidosis with exclusively cardiac phenotype:an Italian perspective[J].Eur Heart J, 2013, 34 (7):520-528.
[20]	Perfetto F, Bergesio F, Grifoni E, et al.Different NT-proBNP circulating levels for different types of cardiac amyloidosis[J].J Cardiovasc Med (Hagerstown), 2016, 17 (11):810-817.
[21]	Costa SP, Beaver TA, Rollor JL, et al.Quantification of the variability associated with repeat measurements of left ventricular two-dimensional global longitudinal strain in a real-world setting[J].J Am SocEchocardiogr, 2014, 27 (1):50-54.
[22]	Belkin RN, Kupersmith AC, Kalique O, et al.A novel two-dimensional echocardiographic finding in cardiac amyloidosis[J].Echocardiography, 2010, 27 (10):1171-1176.
[23]	Koyama J, Falk RH.Prognostic significance of strain Doppler imaging in light-chain amyloidosis[J].JACCCardiovasc Imaging, 2010, 3 (4):333-342.
[24]	Sun JP, Stewart WJ, Yang XS, et al.Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography[J].Am J Cardiol, 2009, 103 (3):411-415.
[25]	Liu D, Hu K, Niemann M, et al.Impact of regional left ven-tricular function on outcome for patients with Al amyloidosis[J].PLoS One, 2013, 8 (3):e56923.
[26]	Liu D, Hu K, Niemann M, et al.Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy[J].Circ Cardiovasc Imaging, 2013, 6 (6):1066-1072.
[27]	Baccouche H, Maunz M, Beck T, et al.Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography[J].Echocardiography, 2012, 29 (6):668-677.
[28]	Saito M, Okayama H, Yoshii T, et al.Clinical significance of global two-dimensional strain as a surrogate parameter of myocardial fibrosis and cardiac events in patients with hypertrophic cardiomyopathy[J].Eur Heart J Cardiovasc Imaging, 2012, 13 (7):617-623.
[29]	Kato TS, Noda A, Izawa H, et al.Discrimination of nonobstructive hypertrophic ardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography[J].Circulation, 2004, 110 (25):3808-3814.
[30]	Kusunose K, Yamada H, Iwase T, et al.Images in cardiovascular medicine:Cardiac magnetic resonance imaging and 2-dimensional speckle tracking echocardiography in secondary cardiac amyloidosis[J].Circ J, 2010, 74 (7):1494-1496.
[31]	Carroll JD, Gaasch WH, McAdam KP.Amyloid cardiomyopathy:characterization by a distinctive voltage/mass relation[J].Am J Cardiol, 1982, 49 (1):9-13.
[32]	Smith BC, Dobson G, Dawson D, et al.Three-dimensionalspeckletrackingof the right ventricle:toward optimal quantification of right ventricular dysfunction in pulmonary hypertension[J].J Am Coll Cardiol, 2014, 64 (1):41-51.
[33]	Bellavia D, Pellikka PA, Dispenzieri A, et al.Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis:a 5-year cohort study[J].Eur Heart JCardiovasc Imaging, 2012, 13 (8):680-689.
[34]	Morris DA, Gailani M, Vaz Pérez A, et al.Left atrial systolic and diastolic dysfunction in heart failure with normal left ventricular ejection fraction[J].J Am Soc Echocardiogr, 2011, 24 (6):651-662.
[35]	Di Bella G, Minutoli F, Madaffari A, et al.Left atrial function in cardiac amyloidosis[J].J Cardiovasc Med, 2016, 17 (2):113-121.
[36]	Fontana M, Banypersad SM, Treibel TA, et al.Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis:a cardiac MR imaging study[J].Radiology, 2015, 277 (2):388-397.
[37]	Gillmore JD, Maurer MS, Falk RH, et al.Nonbiopsy diagnosis of cardiac transthyretin amyloidosis[J].Circulation, 2016, 133 (24):2404-2412.